Broadfin Capital

Edesa Biotech is a clinical-stage company focused on developing treatments for dermatological and anorectal diseases. Its primary focus is on creating novel, safe, and potent alternatives to steroids, particularly for conditions like allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa's lead asset, EB01, is a non-steroidal anti-inflammatory molecule that has shown promising results in clinical studies.

Heron Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative treatments to address unmet medical needs. The company utilizes its proprietary Biochronomer drug delivery technology, which enables sustained release of therapeutic agents over days to weeks with a single administration. Heron's product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for similar indications. Additionally, the company is advancing HTX-011, a dual-acting combination of bupivacaine and meloxicam, currently in Phase III clinical trials for pain management, and HTX-034, aimed at postoperative pain relief. Founded in 1983, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Founded in 2006 and headquartered in Brisbane, California, with a scientific research laboratory in St. Louis, Missouri, the company is known for its innovative approach to cancer treatment. Arch Oncology specializes in anti-CD47 antibodies, which represent a new class of checkpoint inhibitors that engage both the adaptive and innate immune responses. These functionally diverse antibodies not only inhibit immune checkpoints but also selectively target and kill tumor cells, providing patients with new therapeutic options in the fight against cancer.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company headquartered in Raleigh, North Carolina, dedicated to addressing the needs of patients with chronic pain and opioid dependence. Founded in 1997, the company focuses on the development and commercialization of innovative pharmaceutical products, leveraging its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology. This technology allows for the creation of small erodible polymer films designed for effective application to the buccal mucosa. BioDelivery Sciences offers a range of products, including BELBUCA, a buprenorphine buccal film for chronic pain management, and BUNAVAIL, a buprenorphine and naloxone buccal film aimed at treating opioid dependence. Additionally, it provides ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients, and Symproic, which treats opioid-induced constipation in adults with chronic pain. The company's focus on novel drug delivery methods enables it to address important unmet medical needs in pain management and addiction medicine.

Strata Skin Sciences is a medical technology company focused on dermatology, developing, marketing, and distributing devices for treating skin conditions. Its product portfolio centers on the XTRAC excimer laser and VTRAC lamp systems used to treat psoriasis, vitiligo, eczema, and related disorders. The company operates two segments: Dermatology Recurring Procedures, deriving revenue from ongoing use of its devices by dermatologists, and Dermatology Procedures Equipment, from sales of equipment. Distribution is international through distributors and domestic direct sales to physicians. Headquartered in Horsham, Pennsylvania, Strata Skin Sciences traces its origins to 1989.

Iovance Biotherapeutics is a clinical-stage biotechnology company based in San Carlos, California, specializing in the development and commercialization of cancer immunotherapy products that utilize the immune system to target and eliminate cancer cells. The company's primary focus is on tumor-infiltrating lymphocyte (TIL) therapies, with its lead candidates, lifileucel and LN-145, currently undergoing Phase II clinical trials for metastatic melanoma and metastatic cervical cancer, respectively. Iovance is also exploring additional applications of TIL and peripheral blood lymphocyte therapies for various cancers, including squamous cell carcinoma of the head and neck and chronic lymphocytic leukemia, through sponsored trials and collaborative efforts with notable research institutions. Established in 2007, Iovance aims to become a leader in the innovation and delivery of TIL therapies for solid tumors, actively preparing for potential regulatory approvals and market entry in the United States.

Recro Pharma is a clinical‑stage specialty pharmaceutical company focused on developing non‑opioid pain therapeutics, initially targeting the post‑operative setting. Its lead product is an intranasal formulation of Dexmedetomidine, which has completed a Phase Ib placebo‑controlled trial demonstrating pain relief. The company was founded in 2007 and is headquartered in Malvern, Pennsylvania.

ContraFect Corporation is a clinical-stage biotechnology company based in Yonkers, New York, dedicated to developing innovative therapies for life-threatening and drug-resistant infectious diseases. Founded in 2008, the company focuses on creating therapeutic protein and antibody products, primarily using its proprietary lysin and monoclonal antibody platforms. Its lead candidate, CF-301, is an investigational lysin currently in Phase III trials for treating staphylococcus aureus bacteremia, including infections caused by methicillin-resistant strains. Additionally, ContraFect is advancing CF-296, which targets invasive staph aureus infections related to biofilms and osteomyelitis, and CF-370, aimed at gram-negative infections such as those caused by pseudomonas aeruginosa. The company also collaborates with The Rockefeller University to discover new lysin candidates targeting gram-negative pathogens and has initiated an expanded access program to provide exebacase for persistent bacteremia in COVID-19 patients.

Ardelyx is a biopharmaceutical company developing first-in-class, minimally absorbed oral medicines to treat mineral metabolism and metabolic disorders. Based in Fremont, California, founded in 2007. It focuses on non-systemic therapies that act in the intestines to modulate transporters and receptors, aiming to limit systemic exposure. Its lead product Tenapanor targets irritable bowel syndrome with constipation and hyperphosphatemia in chronic kidney disease on dialysis; the program includes Phase 3 trials. The company is pursuing additional candidates such as RDX013 for hyperkalemia, and RDX002 and RDX009 in earlier stages. Ardelyx aims to address cardiorenal and metabolic conditions using a non-systemic platform.

Aralez Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of products primarily in cardiovascular care, pain management, and other specialized areas. The company offers a range of key products such as Fiorinal, Proferrin, Fibricor, Uracyst, Neovisc, and Cambia. Aralez operates primarily in the United States and Canada, with the majority of its revenue generated from the U.S. market. By serving customers worldwide, Aralez Pharmaceuticals aims to address significant medical needs through its targeted therapeutic offerings.

Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, specializing in the development of immunotherapies for cancer and infectious diseases. The company utilizes a unique platform technology involving live, attenuated bacteria engineered to deliver antigen/adjuvant fusion proteins, effectively redirecting immune responses to target cancer cells. Advaxis is advancing several product candidates, including axalimogene filolisbac for HPV-related cancers, currently undergoing Phase II clinical trials for head and neck cancer. Additionally, it is developing ADXS-PSA for prostate cancer and ADXS-NEO, which personalizes treatment by using whole-exome sequencing to identify tumor neoantigens. Other projects include ADXS-HOT, aimed at generating robust anti-cancer immunity, and ADXS-HER2, designed to target HER2-expressing solid tumors. The company has established collaborations and licensing agreements with various organizations, enhancing its research and development efforts.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and licensing of small molecules and biologics aimed at treating and preventing human diseases. The company has two primary portfolios: immunology and central nervous system (CNS). The immunology portfolio includes vaccines and biologics designed to combat infectious diseases, immunosuppression, cancer, and autoimmune disorders. Notable vaccine candidates include TNX-1800, a live replicating vaccine for COVID-19, and TNX-801, a vaccine for smallpox and monkeypox. The CNS portfolio features therapies for pain, neurological, psychiatric, and addiction conditions, including TNX-102 SL, which is in Phase 3 for fibromyalgia management. Other candidates in development target cocaine intoxication, depression, and migraine treatment. Additionally, Tonix is advancing several preclinical candidates aimed at conditions such as post-traumatic stress disorder and organ transplant rejection. Founded in 2007 and based in New York, Tonix is committed to alleviating suffering through innovative therapeutic solutions.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, with a primary focus on gastrointestinal and infectious diseases. The company develops and promotes several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for treating Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill's late-stage clinical development programs include RHB-204, aimed at treating pulmonary nontuberculous mycobacteria infections; RHB-104 for Crohn's disease; and RHB-102 (Bekinda), which has shown promise in Phase 3 studies for acute gastroenteritis and gastritis. Additionally, the company is advancing RHB-107, a serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and opaganib, which is being investigated for various conditions, including COVID-19. Founded in 2009, RedHill Biopharma is committed to innovation in the management of gastrointestinal and infectious diseases.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company based in New York that focuses on developing innovative treatments for neuropsychiatric and neurologic diseases, as well as other central nervous system (CNS) disorders. The company’s lead drug candidate, CAPLYTA, is designed to treat schizophrenia and bipolar disorder, along with behavioral disturbances associated with dementia and autism. Additionally, Intra-Cellular Therapies is working on several other drug candidates, including ITI-002, which targets phosphodiesterase type 1; ITI-214 for Parkinson’s disease; and ITI-333 for substance use disorders, pain, and related psychiatric conditions. The company employs a multidisciplinary approach that combines the expertise of medicinal scientists, pharmacologists, and clinical development scientists to create novel therapies. Intra-Cellular Therapies also utilizes its CNSProfile technology platform to generate molecular signatures for drug compounds, aiding in drug discovery and development, and has engaged in collaborations to investigate antidotes for chemical warfare agents.